- Home
- DAVA vs VIR Comparison
DAVA vs VIR Comparison
Compare DAVA & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- VIR
- Stock Information
- Founded
- DAVA 2000
- VIR 2016
- Country
- DAVA United Kingdom
- VIR United States
- Employees
- DAVA N/A
- VIR N/A
- Industry
- DAVA EDP Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- VIR Health Care
- Exchange
- DAVA Nasdaq
- VIR Nasdaq
- Market Cap
- DAVA 761.0M
- VIR 706.4M
- IPO Year
- DAVA 2018
- VIR 2019
- Fundamental
- Price
- DAVA $12.99
- VIR $4.38
- Analyst Decision
- DAVA Buy
- VIR Strong Buy
- Analyst Count
- DAVA 9
- VIR 8
- Target Price
- DAVA $25.22
- VIR $30.25
- AVG Volume (30 Days)
- DAVA 732.0K
- VIR 1.0M
- Earning Date
- DAVA 09-18-2025
- VIR 08-06-2025
- Dividend Yield
- DAVA N/A
- VIR N/A
- EPS Growth
- DAVA N/A
- VIR N/A
- EPS
- DAVA 0.40
- VIR N/A
- Revenue
- DAVA $1,007,631,882.00
- VIR $19,000,000.00
- Revenue This Year
- DAVA $6.32
- VIR N/A
- Revenue Next Year
- DAVA N/A
- VIR $0.56
- P/E Ratio
- DAVA $31.95
- VIR N/A
- Revenue Growth
- DAVA 5.95
- VIR N/A
- 52 Week Low
- DAVA $11.63
- VIR $4.16
- 52 Week High
- DAVA $34.94
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- DAVA 47.33
- VIR 35.16
- Support Level
- DAVA $12.44
- VIR $4.33
- Resistance Level
- DAVA $13.13
- VIR $4.57
- Average True Range (ATR)
- DAVA 0.61
- VIR 0.22
- MACD
- DAVA 0.11
- VIR -0.02
- Stochastic Oscillator
- DAVA 51.72
- VIR 21.53
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.